Favorable Outcome of Individual Regimens Containing Bedaquiline and Delamanid in Drug-Resistant Tuberculosis: A Systematic Review
Authors:
- 1 January 2023
- journal article
- review article
- Published by Medknow in International Journal of Mycobacteriology
- Vol. 12 (1) , 1-9
Abstract
Background: Drug-resistant tuberculosis (DR-TB) is a public health concern that is difficult to treat, requiring long and complex treatment with highly effective drugs. Bedaquiline and/or delamanid have already shown promising outcomes in patients with DR-TB, increasing the rate of culture conversion and lowering TB-related mortality. Methods: We comprehensively searched and evaluated the effectiveness of individual regimens containing bedaquiline and delamanid on culture conversion and treatment success. We assessed for quality either observational or experimental studies. Results: We identified 14 studies that met the inclusion criteria using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart with 12 observational and 2 experimental studies. Of 1691 DR-TB patients enrolled in the included studies, 1407 of them concomitantly received regimens containing bedaquiline and delamanid. Overall multidrug resistant (MDR), preextensively drug resistant (XDR), and XDR-TB were seen in 21.4%, 44.1%, and 34.5%, respectively. Of 14 studies, 8 of them reported favorable outcomes including sputum culture conversion and cure rate at the end of treatment, meanwhile 6 studies only reported sputum culture conversion. Sputum culture conversion at the end of the 6th month was 63.6%–94.7% for observational studies, and 87.6%–95.0% for experimental studies. The favorable outcome at the end of treatment was 67.5%–91.4%. With high pre-XDR and XDR cases among DR-TB patients with limited treatment options, regimens containing bedaquiline and delamanid provide successful treatment. Conclusion: In DR-TB patients receiving regimens containing bedaquiline and delamanid, favorable outcomes were high including sputum conversion and cure rate.Keywords
This publication has 45 references indexed in Scilit:
- Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trialThe Lancet Respiratory Medicine, 2019
- Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosisEuropean Respiratory Journal, 2018
- Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trialPLOS ONE, 2018
- Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic reviewEuropean Respiratory Journal, 2018
- Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center StudyThe American Journal of Tropical Medicine and Hygiene, 2018
- Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort studyThe Lancet Infectious Diseases, 2018
- Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosisThe International Journal of Tuberculosis and Lung Disease, 2018
- Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in KoreaEuropean Respiratory Journal, 2018
- Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugsThe International Journal of Tuberculosis and Lung Disease, 2018
- Delamanid Kills Dormant Mycobacteria In Vitro and in a Guinea Pig Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2017